TITLE

Review: Fenoldopam reduces acute kidney injury and death in critical illness: COMMENTARY

AUTHOR(S)
Adhikari, Neill K. J.; Friedrich, Jan O.
PUB. DATE
May 2007
SOURCE
ACP Journal Club;May/Jun2007, Vol. 146 Issue 3, p58
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article comments on the study which evaluated fenoldopam to prevent acute renal failure in high-risk patients. The author cited that the research suggested patient-important benefits and a clinically tolerable increased for hypotension. It was found out that fenoldopam reduces acute kidney injury and death in critical illness.
ACCESSION #
25169095

 

Related Articles

  • Influence of carvedilol on chronic renal failure progression in spontaneously hypertensive rats with adriamycin nephropathy. Jovanovic, D.; Jovovic, D.; Mihailovic-Stanojevic, N.; Miloradovic, Z.; Dimitrijevic, J.; Maksic, N.; Djukanovic, L. // Clinical Nephrology;2005, Vol. 63 Issue 6, p446 

    Background: In this study, the effects of carvedilol, antihypertensive (α-β blocker) agent with antiproliferative and anti-oxidative properties, on slowing down of chronic renal failure (CRF) progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy were...

  • Study design and methods for a clinical trial of an oral carbonaceous adsorbent used to prevent the progression of chronic kidney disease (CAP-KD). Morita, Satoshi; Fukuhara, Shunichi; Akizawa, Tadao; Asano, Yasushi; Kurokawa, Kiyoshi // Clinical & Experimental Nephrology;Sep2005, Vol. 9 Issue 3, p219 

    Background. The number of patients with chronic kidney disease (CKD) in Japan is currently rising. Therefore, measures to control the progression of CKD from a predialysis condition to endstage renal failure are urgently required. We are conducting a clinical trial to investigate the efficacy of...

  • Finding the Best Diabetes Meds for Kidney Disease Patients.  // Healthy Years;Feb2012, Vol. 9 Issue 2, p6 

    The article discusses the findings of study on the best diabetes medications for patients with kidney disease. The study has suggested that diabetes drugs sitagliptin (Januvia) and glipizide (Glucotrol) may not cause considerable damage to kidneys. It compared the efficacy and safety of both...

  • Benazepril was effective and safe for advanced chronic kidney disease without diabetes.  // ACP Journal Club;Jul/Aug2006, Vol. 145 Issue 1, p19 

    The article presents information on a study, which focuses on the efficacy and safety of benazepril for advanced chronic renal insufficiency. The study was mainly concentrated on 224 patients with 18 to 70 years of age in a hospital in Guangzhou, China. The controlled group of the study were...

  • Benazepril was effective and safe for advanced chronic kidney disease without diabetes: COMMENTARY. Hsu, Chi-yuan // ACP Journal Club;Jul/Aug2006, Vol. 145 Issue 1, p19 

    The article presents the author's views on a study, which focuses on the efficacy and safety of benazepril for advanced chronic renal insufficiency. He informs that the use of angiotensin-converting enzyme (ACT) inhibitors is often found to retard chronic kidney disease (CKD) progression....

  • Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial. Tanaka, Kenichi; Nakayama, Masaaki; Kanno, Makoto; Kimura, Hiroshi; Watanabe, Kimio; Tani, Yoshihiro; Hayashi, Yoshimitsu; Asahi, Koichi; Terawaki, Hiroyuki; Watanabe, Tsuyoshi // Clinical & Experimental Nephrology;Dec2015, Vol. 19 Issue 6, p1044 

    Background: Hyperuricemia is associated with the onset of chronic kidney disease (CKD) and renal disease progression. Febuxostat, a novel, non-purine, selective xanthine oxidase inhibitor, has been reported to have a stronger effect on hyperuricemia than conventional therapy with allopurinol....

  • Microalbuminuria: target for renoprotective therapy PRO. Roscioni, Sara S; Lambers Heerspink, Hiddo J; de Zeeuw, Dick // Kidney International;Jul2014, Vol. 86 Issue 1, p40 

    Drug efficacy is ascertained using clinically meaningful outcomes that directly affect the well-being of patients. However, in studies of chronic kidney disease progression, clinically meaningful outcomes like end-stage renal disease take a long time to occur. The use of surrogate end...

  • Uremic myopathy. Campistol, Josep M. // Kidney International;Nov2002, Vol. 62 Issue 5, p1901 

    Reports on a case of a 52-year-old man with end-stage renal disease secondary to chronic nephroangiosclerosis. Medical history of the patient; Clinical presentation of the disease; Method of treatment.

  • 365. Appropriate planning critical to meet needs of expanding ESRD population. Xue, J.L.; Ma, J.Z.; Louis, T.A. // Kidney;May/Jun2002, Vol. 11 Issue 3, p120 

    Provides information on a study which predicted the number of patients with end-stage renal disease in the U.S. by 2010. Methodology; Results; Conclusion.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics